- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03624972
Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study
15 de marzo de 2021 actualizado por: Fox Chase Cancer Center
Enhancing Patient-Provider Communication About Sexual Concerns in Breast Cancer: Patient Intervention Study
The goal of this study is to evaluate an educational video intervention (called Starting the Conversation) aimed to enhance breast cancer patients' beliefs about and communication with respect to sexual concerns.
In the current study, 128 breast cancer outpatients will be randomized to either participate in the video intervention and to receive a resource guide addressing sexual and menopausal health or to receive the resource guide alone.
Patients will be asked to participate in the video and/or read through the resource guide prior to their clinic visit with their breast cancer provider.
The investigators will examine effects of the interventions on patients' beliefs about communication about sexual health and on patients' communication about sexual health during clinic visits with their providers.
Secondarily, the investigators will examine effects of the interventions on sexual outcomes and other health outcomes, including psychological well-being and health-related QOL.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
153
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Fox Chase Cancer Center
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
21 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Femenino
Descripción
Inclusion Criteria:
- Receiving any treatment for breast cancer or have completed acute treatment for breast cancer < 10 years ago
- Attending clinic visits in the course of follow-up care (i.e., not an initial consult visit)
- Willing to have clinic visit audio recorded
Exclusion Criteria:
- Unable to speak English
- Eastern Cooperative Oncology Group (ECOG) Performance score > 2 OR too ill to participate as judged by physician, self-report, or observation of the research team member
- Overt cognitive dysfunction or psychiatric disturbance or severe mental illness (e.g., dementia, suicidal behavior, or psychosis), as observed or judged by the researcher or referring source.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Resources Only
Patients will receive a list of resources on sexual and menopausal health in breast cancer.
They will be asked to review the resources before their next clinic visit.
|
Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal & sexual health clinic.
|
Experimental: Resources + Video
Patients will receive a list of web resources on sexual and menopausal health in breast cancer.
In addition to the resources, patients will be asked to view an online video called "Starting the Conversation" and to complete an accompanying workbook.
Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit.
|
Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal & sexual health clinic.
The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
|
Sin intervención: Clinician Arm
Clinicians were consented in order to have their clinic visits audio recorded.
No outcomes data were collected from clinician participants.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Self-Reported Self-Efficacy for Communicating About Sexual Health Issues
Periodo de tiempo: 2 weeks
|
Two items assessed patients' self-efficacy (confidence) for communicating with their breast cancer clinician about sexual health concerns in terms of either talking (item 1) or asking (item 2) about sexual health.
Response options used an 11-point scale (0=not at all confident/not at all to 10=extremely confident/very much).
Mean scores across the two items were used, ranging from 0-10.
Higher scores indicate higher self-efficacy.
|
2 weeks
|
Self-Reported Self-Efficacy for Communicating About Sexual Health Issues
Periodo de tiempo: 2 months
|
Two items assessed patients' self-efficacy (confidence) for communicating with their breast cancer clinician about sexual health concerns in terms of either talking (item 1) or asking (item 2) about sexual health.
Response options used an 11-point scale (0=not at all confident/not at all to 10=extremely confident/very much).
Mean scores across the two items were used, ranging from 0-10.
Higher scores indicate higher self-efficacy.
|
2 months
|
Self-Reported Outcome Expectancies for Sexual Health Communication
Periodo de tiempo: 2 weeks
|
Five items assessed the belief that discussing sexual health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 weeks
|
Self-Reported Outcome Expectancies for Sexual Health Communication
Periodo de tiempo: 2 months
|
Five items assessed the belief that discussing sexual health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 months
|
Number of Patients Who Asked at Least One Question About Sexual Health at Their Clinic Visit
Periodo de tiempo: 2 weeks
|
As coded from clinic visit audio, the number of patients who ask at least one question about sexual health.
|
2 weeks
|
Number of Patients Who Initiate Conversation About Sexual Health in Their Clinic Visit
Periodo de tiempo: 2 weeks
|
As coded from clinic visit audio, the number of patients who raise the topic of sexual health during their encounter (out of encounters where a sexual health discussion occurred).
|
2 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Recruitment Rates (Feasibility)
Periodo de tiempo: baseline
|
Recruitment rates, as measured by percentage of patients enrolled (i.e., baselined) out of eligible patients approached for the study.
|
baseline
|
Retention Rates (Feasibility)
Periodo de tiempo: 2 weeks
|
Retention rates, as measured by percentage of patients who remain on study for 2-week follow-up assessment.
|
2 weeks
|
Retention Rates (Feasibility)
Periodo de tiempo: 2 months
|
Retention rates, as measured by percentage of patients who remain on study for 2-month follow-up assessment.
|
2 months
|
Intervention Acceptability
Periodo de tiempo: 2 weeks
|
Acceptability of intervention, as measured through the item "Overall, how satisfied were you with this program?".
Responses options include Very Satisfied, Satisfied, Dissatisfied, and Very Dissatisfied.
Responses of "satisfied" or "very satisfied" indicate acceptability.
Number of patients reporting acceptability and number of patients not reporting acceptability are presented.
|
2 weeks
|
Sexual Activity
Periodo de tiempo: 2 months
|
Sexual activity was measured by a single item asking (yes/no) whether the participant had any kind of sexual activity in the past 30 days.
|
2 months
|
Sexual Function
Periodo de tiempo: 2 months
|
Sexual function was assessed using the Lubrication, Vaginal Discomfort, Satisfaction, and Interest domain scores from the Patient-Reported Outcomes Measurement Information System Sexual Function and Satisfaction scale (PROMIS SexFS) Brief Profile Version 2.0.
Scores are converted to a T-score metric where a score of 50 equates to the mean of the U.S. population of sexually active adults (SD=10).
Higher scores for all domains except Vaginal Discomfort signify better function.
|
2 months
|
General Self-Efficacy for Communication With Provider
Periodo de tiempo: 2 months
|
Patients' self-efficacy for communicating with provider generally, as measured through the Perceived Efficacy in Patient-Physician Interactions Scale (PEPPI-5).
The PEPPI-5 is a five-item scale that measures patient confidence in communicating with providers.
Response options are on a scale from 1 (Not at All Confident) to 5 (Very Confident) and are summed for a total self-efficacy score (Range: 5-25).
Higher scores indicate higher self-efficacy.
|
2 months
|
Barriers to Communicating About Sexual Health
Periodo de tiempo: 2 months
|
Patient barriers to communication about sexual health, as measured through a 13-item scale.
Scale items cover potential reasons a patient might not want to discuss sexual health concerns with her provider (e.g., "I might become embarrassed").
Items are scored on a 1-5 scale where 1=Strongly Disagree and 5=Strongly Disagree.
A total barrier score will be taken from this scale (Range: 13-65).
Higher scores indicate more perceived barriers to communication.
|
2 months
|
Self-Reported Anxiety
Periodo de tiempo: 2 months
|
Patients self-reported anxiety, as measured through anxiety subscale of the Hospital Anxiety & Depression Scale (HADS).
The anxiety subscale consists of 7 items that are scored from 0 to 3. Summed scores range from 0 to 21, with higher scores indicating higher levels of anxiety.
|
2 months
|
Self-Reported Depression
Periodo de tiempo: 2 months
|
Patients self-reported depression, as measured through depression subscale of the Hospital Anxiety & Depression Scale (HADS).
The depression subscale consists of 7 items that are scored from 0 to 3. Summed scores range from 0 to 21, with higher scores indicating higher levels of depression.
|
2 months
|
Self-Reported Quality of Life
Periodo de tiempo: 2 months
|
Quality of life, as measured through the Abbreviated Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) total score.
The FACT-B contains 23 items about physical, functional, and emotional well-being in the context of breast cancer.
Scale items are scored from 0 to 4. Summed scores run from 0 to 92, with higher scores indicating higher quality of life.
|
2 months
|
Self-Reported Self-Efficacy for Communicating About About Treatment Side Effects
Periodo de tiempo: 2 weeks
|
Patients' self-reported self-efficacy for communication about treatment side effects with their breast cancer provider.
The items about treatment side effects consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about treatment side effects and asking her provider about treatment side effects.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 weeks
|
Self-Reported Self-Efficacy for Communicating About About Treatment Side Effects
Periodo de tiempo: 2 months
|
Patients' self-reported self-efficacy for communication about treatment side effects with their breast cancer provider.
The items about treatment side effects consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about treatment side effects and asking her provider about treatment side effects.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 months
|
Self-Reported Self-Efficacy for Communicating About About Menopausal Health
Periodo de tiempo: 2 weeks
|
Patients' self-reported self-efficacy for communication about menopausal health with their breast cancer provider.
The items about menopausal health consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about menopausal health and asking her provider about menopausal health.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 weeks
|
Self-Reported Self-Efficacy for Communicating About About Menopausal Health
Periodo de tiempo: 2 months
|
Patients' self-reported self-efficacy for communication about menopausal health with their breast cancer provider.
The items about menopausal health consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about menopausal health and asking her provider about menopausal health.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 months
|
Self-Reported Outcome Expectancies for Communication About Treatment Side Effects
Periodo de tiempo: 2 weeks
|
Five items assessed the belief that discussing treatment side effects with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 weeks
|
Self-Reported Outcome Expectancies for Communication About Treatment Side Effects
Periodo de tiempo: 2 months
|
Five items assessed the belief that discussing treatment side effects with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 months
|
Self-Reported Outcome Expectancies for Communication About Menopausal Health
Periodo de tiempo: 2 weeks
|
Five items assessed the belief that discussing menopausal health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 weeks
|
Self-Reported Outcome Expectancies for Communication About Menopausal Health
Periodo de tiempo: 2 months
|
Five items assessed the belief that discussing menopausal health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
27 de mayo de 2018
Finalización primaria (Actual)
31 de diciembre de 2019
Finalización del estudio (Actual)
31 de diciembre de 2019
Fechas de registro del estudio
Enviado por primera vez
20 de julio de 2018
Primero enviado que cumplió con los criterios de control de calidad
7 de agosto de 2018
Publicado por primera vez (Actual)
10 de agosto de 2018
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
16 de marzo de 2021
Última actualización enviada que cumplió con los criterios de control de calidad
15 de marzo de 2021
Última verificación
1 de marzo de 2021
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 14-833-02
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Mujer con cáncer de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
Ensayos clínicos sobre Sexual and Menopausal Health Resources
-
Brigham and Women's HospitalNational Aeronautics and Space Administration (NASA)Terminado
-
AIDS Arms Inc.Terminado